People with myotonic dystrophy experience progressive muscle weakness and repeated episodes of painless muscle stiffness called myotonia.

Investigators at Massachusetts General Hospital (MGH) recently used a targeted drug to restore muscle strength and correct myotonia in mice with myotonic dystrophy. The research, which is published in Nature Communications, could lead to new treatments for affected patients.

Myotonia in myotonic dystrophy is caused by abnormal processing (or splicing) of the transcript created from the gene that codes for the muscle chloride channel Clcn1, a protein that controls the flow of chloride ions into muscle cells.

The abnormal splicing leads to a truncated and poorly functioning Clcn1.

Also, the degree of weakness in patients with myotonic dystrophy is associated with higher amounts of oxidative, rather than glycolytic, muscle fibers. These fibers differ in how they obtain energy for contraction.

To correct the abnormal splicing in mice with myotonic dystrophy, a team led by Thurman Wheeler, MD, a neuromuscular researcher at MGH and an associate professor of Neurology at Harvard Medical School, used a genetic therapy involving small pieces of DNA called antisense oligonucleotides (ASOs).

The ASOs were based on a code that targets the abnormal splicing of Clcn1, and when injected directly into the animals’ muscles, the ASOs corrected the abnormality, boosted the abundance of functional Clcn1, increased the amount of glycolytic muscle fibers, and restored muscle health.

“Our findings show that muscle fiber type transitions in myotonic dystrophy result from myotonia and are reversible,” says Wheeler. “Our results also support Clcn1-targeting therapies as a way to increase strength and reduce muscle injury in patients.”

Additional co-authors include Ningyan Hu, Eunjoo Kim, and Layal Antoury.

This work was supported by the Elaine and Richard Slye Fund and the Muscular Dystrophy Association.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

what is 2 plus 5?

Explore More

Surprising finding in glioblastomas | ScienceDaily

Glioblastomas are highly aggressive, usually incurable brain tumors. If all therapeutic options are exhausted, patients have an average life expectancy of less than two years. Now researchers from the German

Molecular mechanism behind MS and other autoimmune diseases

More than two decades ago, a research team in the lab of David Hafler, a Yale researcher who at the time was at Harvard, discovered a type of T cell

Study reveals a protein called snail may play a role in healing brain injury

A new study published in Proceedings of the National Academy of Sciences Nexus provides a better understanding of how the brain responds to injuries. Researchers at the George Washington University